Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 3/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PDIA6 | Q15084 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14526667 | 0.94 | PPARA (0.41) | PPARAALDH1A1F2PPARDPDIA6 | |
| SCHEMBL14526664 | 0.87 | PPARG (0.47) | PPARAALDH1A1F2 | |
| SCHEMBL5660178 | 0.85 | PPARA (0.53) | PPARAPPARD | |
| SCHEMBL14526665 | 0.81 | PPARA (0.43) | PPARAALDH1A1CA1CA2CA9 | |
| SCHEMBL5660952 | 0.81 | PPARA (0.54) | PPARAALDH1A1PPARDCYP1A2CYP3A4 | |
| SCHEMBL5659323 | 0.80 | PPARA (0.54) | PPARAPPARD | |
| SCHEMBL5660220 | 0.80 | CA1 (0.42) | ALDH1A1CA1CA2CA9F2 | |
| SCHEMBL5660643 | 0.77 | PPARA (0.52) | PPARAALDH1A1PPARDCYP1A2CYP3A4 | |
| SCHEMBL3838916 | 0.77 | CA2 (0.60) | ALDH1A1CA1CA2CA9 | |
| SCHEMBL15959430 | 0.76 | MAPK1 (0.40) | PPARAALDH1A1MEN1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | GPR119, NR1H3, NR1H2 | PPARA 251/4885ALDH1A1 2751/4885CA1 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.